DIM
ADPT icon

DLK Investment Management’s Adaptive Biotechnologies ADPT Stock Holding History

DLK Investment Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$246K Sell
8,500
-1,600
-16% -$39.3K 0.09% 71
2026
Q2 		$36.6K Buy
+10,100
New +$155K 0.02% 92
2024
Q4 		– Sell
-10,100
Closed -$51.7K – 91
2024
Q3 		$51.7K Hold
10,100
– – 0.02% 97
2024
Q2 		$36.6K Buy
+10,100
New +$32.1K 0.02% 97

Other funds holding ADPT

WF
WoodTrust Financial Wisconsin Rapids, Wisconsin $825M AUM 20.13% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
GA
GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

DLK Investment Management's ADPT Position: Q3 2026 in Review

DLK Investment Management reduced its Adaptive Biotechnologies (ADPT) stake by 16% in Q3 2026, selling an estimated $39.3K and leaving 8,500 shares worth $246K. The position accounts for 0.09% of the portfolio, ranked #71.

DLK Investment Management first reported a position in ADPT in Q2 2024 and has held it in 4 quarters since. 8 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • DLK Investment Management held 8,500 shares of Adaptive Biotechnologies worth $246K as of Q3 2026.
  • DLK Investment Management sold 1,600 Adaptive Biotechnologies shares in Q3 2026, an estimated $39.3K.
  • Adaptive Biotechnologies made up 0.09% of DLK Investment Management's portfolio in Q3 2026, its #71 holding.
  • DLK Investment Management first reported a position in Adaptive Biotechnologies in Q2 2024 and has held it in 4 quarters since.
  • 8 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on DLK Investment Management's 13F filing for Q3 2026, filed 9 Oct 2026.